<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01097655</url>
  </required_header>
  <id_info>
    <org_study_id>P06-131</org_study_id>
    <nct_id>NCT01097655</nct_id>
  </id_info>
  <brief_title>Study on the Usage, Dosing, Tolerability, and Effectiveness of Kaletra Tablet</brief_title>
  <official_title>Use of KALETRA® Tablets in Adult HIV-infected Patients: Data From the Multicenter Star/Stella Cohort</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AbbVie (prior sponsor, Abbott)</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Veeda Clinical Research</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>AbbVie</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to observe and collect data on the usage, dosing,
      tolerability, and effectiveness of Kaletra (lopinavir/ritonavir) tablets in human
      immunodeficiency virus (HIV)-infected patients. In some patients, the study is to show the
      impact on tolerability of changing therapy to Kaletra tablets from other regimens.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study was designed as a non-interventional observational study. Kaletra was prescribed
      in the usual manner in accordance with the terms of the local market authorization with
      regards to dose, population and indication as well as local guidelines.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2006</start_date>
  <completion_date type="Actual">January 2016</completion_date>
  <primary_completion_date type="Actual">January 2016</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in Absolute Cluster of Differentiation 4 (CD4) Cell Count</measure>
    <time_frame>Baseline (Week 0) to Week 144</time_frame>
    <description>Changes in participants' CD4 cell counts were assessed by measuring the change from Baseline in the number of CD4 cells at scheduled visits planned as part of routine care.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in HIV-1 Ribonucleic Acid (RNA) Viral Load</measure>
    <time_frame>Baseline (Week 0) to Week 144</time_frame>
    <description>Changes in participants' HIV-1 RNA viral load were assessed by measuring the change from Baseline at scheduled visits planned as part of routine care.</description>
  </primary_outcome>
  <other_outcome>
    <measure>Prevalence of Adverse Events (Weeks 0-144), Per Event</measure>
    <time_frame>Weeks 0 to 144</time_frame>
    <description>Percentage of overall number of adverse events experienced during Weeks 0-144 by adverse event type. Doctors asked participants for adverse events, grouped them into categories given in the electronic case report form (eCRF). The list of adverse events included in the eCRF were hypertriglyceridemia, hypercholesterolemia, low high density lipoprotein (HDL) cholesterol, high low density lipoprotein (LDL) cholesterol, hyperglycemia, hyperbilirubinemia, elevated aspartate aminotransferase (AST), elevated alanine aminotransferase (ALT), elevated gamma glutamyl transferase (γGT), elevated alkaline phosphatase, stomatitis, nausea, vomiting, diarrhea, abdominal pain, mood disorder, neurocerebellar disorder, neurocontrol disorder, headache, fatigue, fever, other (listed as 'not specified').</description>
  </other_outcome>
  <other_outcome>
    <measure>Prevalence of Adverse Events (Weeks 0-144), Per Participant</measure>
    <time_frame>Weeks 0 to 144</time_frame>
    <description>Percentage of participants who experienced at least 1 adverse event during Weeks 0-144 by adverse event type. Doctors asked participants for adverse events, grouped them into categories given in the eCRF. The list of adverse events included in the eCRF were hypertriglyceridemia, hypercholesterolemia, low HDL cholesterol, high LDL cholesterol, hyperglycemia, hyperbilirubinemia, elevated AST, elevated ALT, elevated γGT, elevated alkaline phosphatase, stomatitis, nausea, vomiting, diarrhea, abdominal pain, mood disorder, neurocerebellar disorder, neurocontrol disorder, headache, fatigue, fever, other (listed as 'not specified').</description>
  </other_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">3049</enrollment>
  <condition>Human Immunodeficiency Virus</condition>
  <arm_group>
    <arm_group_label>HIV-infected Participants</arm_group_label>
    <description>HIV-infected participants starting with Kaletra tablets.
Participants included 3 subgroups:
antiretroviral therapy (ART) treatment-naïve participants starting with Kaletra tablets
participants receiving their first protease inhibitor (PI)-containing regimen (apart from Kaletra) pretreated with any non nucleoside reverse transcriptase inhibitor (NNRTI)-containing or nucleoside reverse transcriptase inhibitor (NRTI)-containing regimen
participants pretreated with a PI-containing regimen (apart from Kaletra).</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        -  Community sample; HIV-infected patients

          -  For Belgium: AIDS references centers (probability sample)
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with HIV infection

          -  Patients that will be treated with Kaletra tablets independent from their
             participation in this study

        Exclusion Criteria:

          -  Hypersensitivity against Kaletra or other ingredients

          -  Severe liver insufficiency

          -  No concommitant astemizole, terfenadine, oral midazolam, triazolam, cisapride,
             pimozide, amiodarone, ergotamine, dihydroergotamine, ergometrine, methylergometrine,
             vardenafil and St. John's wort

          -  Patients who received more than 1 protease inhibitor during their therapy history
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sandra Bloch, MD</last_name>
    <role>Study Director</role>
    <affiliation>AbbVie Deutschland GmbH &amp; Co. KG, Medical Department</affiliation>
  </overall_official>
  <removed_countries>
    <country>Belgium</country>
    <country>Germany</country>
    <country>Israel</country>
  </removed_countries>
  <link>
    <url>http://rxabbvie.com</url>
  </link>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 26, 2010</study_first_submitted>
  <study_first_submitted_qc>March 31, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 2, 2010</study_first_posted>
  <results_first_submitted>January 18, 2017</results_first_submitted>
  <results_first_submitted_qc>May 18, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">May 23, 2017</results_first_posted>
  <last_update_submitted>May 18, 2017</last_update_submitted>
  <last_update_submitted_qc>May 18, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 23, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Tablets</keyword>
  <keyword>Infection</keyword>
  <keyword>Non Nucleoside Reverse Transcriptase Inhibitor</keyword>
  <keyword>Tolerability</keyword>
  <keyword>Viral load</keyword>
  <keyword>Human immunodeficiency Virus</keyword>
  <keyword>Effectiveness</keyword>
  <keyword>Treatment-naïve</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Immunologic Deficiency Syndromes</mesh_term>
    <mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Reverse Transcriptase Inhibitors</mesh_term>
    <mesh_term>Lopinavir</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>HIV-infected Participants</title>
          <description>HIV-infected participants starting with Kaletra tablets.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="3049"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3039">participants included for analysis</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Subject Documented Twice</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Did Not Meet Inclusion Criteria</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>HIV-infected Participants</title>
          <description>HIV-infected participants starting with Kaletra tablets.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="3039"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <population>participants with age recorded at Baseline</population>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="2896"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40.7" spread="10.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="3039"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="595"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2444"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Absolute Cluster of Differentiation 4 (CD4) Cell Count</title>
        <description>Changes in participants' CD4 cell counts were assessed by measuring the change from Baseline in the number of CD4 cells at scheduled visits planned as part of routine care.</description>
        <time_frame>Baseline (Week 0) to Week 144</time_frame>
        <population>Participants with an assessment at Baseline. Number analyzed=participants with an assessment at given time point.</population>
        <group_list>
          <group group_id="O1">
            <title>HIV-infected Participants</title>
            <description>HIV-infected participants starting with Kaletra tablets.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Absolute Cluster of Differentiation 4 (CD4) Cell Count</title>
          <description>Changes in participants' CD4 cell counts were assessed by measuring the change from Baseline in the number of CD4 cells at scheduled visits planned as part of routine care.</description>
          <population>Participants with an assessment at Baseline. Number analyzed=participants with an assessment at given time point.</population>
          <units>cells/μL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2981"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change at Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2378"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.8" spread="145.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2391"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="133.3" spread="148.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2240"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="160.5" spread="177.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 36</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2004"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="185.9" spread="181.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 48</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1867"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="213.6" spread="225.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 60</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1694"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="228.4" spread="204.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 72</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1545"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="250.1" spread="205.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 84</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1370"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="263.8" spread="214.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 96</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1340"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="276.3" spread="212.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 108</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1222"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="291.0" spread="247.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 120</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1171"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="294.3" spread="216.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 132</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1110"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="303.8" spread="229.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 144</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1173"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="316.1" spread="228.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in HIV-1 Ribonucleic Acid (RNA) Viral Load</title>
        <description>Changes in participants' HIV-1 RNA viral load were assessed by measuring the change from Baseline at scheduled visits planned as part of routine care.</description>
        <time_frame>Baseline (Week 0) to Week 144</time_frame>
        <population>Participants with an assessment at Baseline. Number analyzed=participants with an assessment at given time point.</population>
        <group_list>
          <group group_id="O1">
            <title>HIV-infected Participants</title>
            <description>HIV-infected participants starting with Kaletra tablets.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in HIV-1 Ribonucleic Acid (RNA) Viral Load</title>
          <description>Changes in participants' HIV-1 RNA viral load were assessed by measuring the change from Baseline at scheduled visits planned as part of routine care.</description>
          <population>Participants with an assessment at Baseline. Number analyzed=participants with an assessment at given time point.</population>
          <units>log copies/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2959"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change at Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2323"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.90" spread="0.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2296"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.53" spread="1.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2089"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.83" spread="1.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 36</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1821"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.89" spread="1.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 48</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1693"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.89" spread="1.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 60</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1532"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.93" spread="1.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 72</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1377"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.92" spread="1.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 84</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1230"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.92" spread="1.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 96</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1198"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.93" spread="1.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 108</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1093"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.93" spread="1.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 120</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1070"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.92" spread="1.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 132</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="999"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.94" spread="1.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 144</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1049"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.97" spread="1.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Prevalence of Adverse Events (Weeks 0-144), Per Event</title>
        <description>Percentage of overall number of adverse events experienced during Weeks 0-144 by adverse event type. Doctors asked participants for adverse events, grouped them into categories given in the electronic case report form (eCRF). The list of adverse events included in the eCRF were hypertriglyceridemia, hypercholesterolemia, low high density lipoprotein (HDL) cholesterol, high low density lipoprotein (LDL) cholesterol, hyperglycemia, hyperbilirubinemia, elevated aspartate aminotransferase (AST), elevated alanine aminotransferase (ALT), elevated gamma glutamyl transferase (γGT), elevated alkaline phosphatase, stomatitis, nausea, vomiting, diarrhea, abdominal pain, mood disorder, neurocerebellar disorder, neurocontrol disorder, headache, fatigue, fever, other (listed as 'not specified').</description>
        <time_frame>Weeks 0 to 144</time_frame>
        <group_list>
          <group group_id="O1">
            <title>HIV-infected Participants</title>
            <description>HIV-infected participants starting with Kaletra tablets.</description>
          </group>
        </group_list>
        <measure>
          <title>Prevalence of Adverse Events (Weeks 0-144), Per Event</title>
          <description>Percentage of overall number of adverse events experienced during Weeks 0-144 by adverse event type. Doctors asked participants for adverse events, grouped them into categories given in the electronic case report form (eCRF). The list of adverse events included in the eCRF were hypertriglyceridemia, hypercholesterolemia, low high density lipoprotein (HDL) cholesterol, high low density lipoprotein (LDL) cholesterol, hyperglycemia, hyperbilirubinemia, elevated aspartate aminotransferase (AST), elevated alanine aminotransferase (ALT), elevated gamma glutamyl transferase (γGT), elevated alkaline phosphatase, stomatitis, nausea, vomiting, diarrhea, abdominal pain, mood disorder, neurocerebellar disorder, neurocontrol disorder, headache, fatigue, fever, other (listed as 'not specified').</description>
          <units>percentage of adverse events</units>
          <param>Number</param>
          <units_analyzed>Adverse Events</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3039"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Adverse Events</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44499"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Hypertriglyceridemia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hypercholesterolemia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low HDL Cholesterol</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High LDL Cholesterol</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hyperglycemia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hyperbilirubinemia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Elevated AST</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Elevated ALT</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Elevated γGT</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Elevated Alkaline Phosphatase</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stomatitis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nausea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vomiting</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diarrhea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Abdominal Pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mood Disorder</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neurocerebellar Disorder</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neurocontrol Disorder</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Specified</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Prevalence of Adverse Events (Weeks 0-144), Per Participant</title>
        <description>Percentage of participants who experienced at least 1 adverse event during Weeks 0-144 by adverse event type. Doctors asked participants for adverse events, grouped them into categories given in the eCRF. The list of adverse events included in the eCRF were hypertriglyceridemia, hypercholesterolemia, low HDL cholesterol, high LDL cholesterol, hyperglycemia, hyperbilirubinemia, elevated AST, elevated ALT, elevated γGT, elevated alkaline phosphatase, stomatitis, nausea, vomiting, diarrhea, abdominal pain, mood disorder, neurocerebellar disorder, neurocontrol disorder, headache, fatigue, fever, other (listed as 'not specified').</description>
        <time_frame>Weeks 0 to 144</time_frame>
        <group_list>
          <group group_id="O1">
            <title>HIV-infected Participants</title>
            <description>HIV-infected participants starting with Kaletra tablets.</description>
          </group>
        </group_list>
        <measure>
          <title>Prevalence of Adverse Events (Weeks 0-144), Per Participant</title>
          <description>Percentage of participants who experienced at least 1 adverse event during Weeks 0-144 by adverse event type. Doctors asked participants for adverse events, grouped them into categories given in the eCRF. The list of adverse events included in the eCRF were hypertriglyceridemia, hypercholesterolemia, low HDL cholesterol, high LDL cholesterol, hyperglycemia, hyperbilirubinemia, elevated AST, elevated ALT, elevated γGT, elevated alkaline phosphatase, stomatitis, nausea, vomiting, diarrhea, abdominal pain, mood disorder, neurocerebellar disorder, neurocontrol disorder, headache, fatigue, fever, other (listed as 'not specified').</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3039"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Hypertriglyceridemia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hypercholesterolemia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low HDL Cholesterol</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High LDL Cholesterol</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hyperglycemia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hyperbilirubinemia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Elevated AST</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Elevated ALT</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Elevated γGT</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Elevated Alkaline Phosphatase</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stomatitis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nausea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vomiting</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diarrhea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Abdominal Pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mood Disorder</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neurocerebellar Disorder</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neurocontrol Disorder</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Specified</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Through Week 144</time_frame>
      <desc>Serious adverse events only were collected and coded by MedDRA. Per protocol, the number of participants with events were collected for each event, but from the source documentation to tell how many of the participants are counted in more than one adverse event (i.e., it is not possible to compute the Total Number of Participants Affected). Please see Outcome Measures 3 and 4 for these data.</desc>
      <group_list>
        <group group_id="E1">
          <title>HIV-infected Participants</title>
          <description>HIV-infected participants starting with Kaletra tablets.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 18.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="79" subjects_at_risk="3039"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>ANAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3039"/>
              </event>
              <event>
                <sub_title>EOSINOPHILIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3039"/>
              </event>
              <event>
                <sub_title>HAEMOLYTIC ANAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3039"/>
              </event>
              <event>
                <sub_title>LYMPHADENITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3039"/>
              </event>
              <event>
                <sub_title>LYMPHADENOPATHY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3039"/>
              </event>
              <event>
                <sub_title>MACROCYTOSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3039"/>
              </event>
              <event>
                <sub_title>PANCYTOPENIA</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3039"/>
              </event>
              <event>
                <sub_title>PLASMACYTOSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3039"/>
              </event>
              <event>
                <sub_title>THROMBOCYTOPENIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3039"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>ANGINA PECTORIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3039"/>
              </event>
              <event>
                <sub_title>ARTERIOSCLEROSIS CORONARY ARTERY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3039"/>
              </event>
              <event>
                <sub_title>ATRIOVENTRICULAR BLOCK</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3039"/>
              </event>
              <event>
                <sub_title>ATRIOVENTRICULAR BLOCK SECOND DEGREE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3039"/>
              </event>
              <event>
                <sub_title>ATRIOVENTRICULAR DISSOCIATION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3039"/>
              </event>
              <event>
                <sub_title>BRADYCARDIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3039"/>
              </event>
              <event>
                <sub_title>BUNDLE BRANCH BLOCK RIGHT</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3039"/>
              </event>
              <event>
                <sub_title>CARDIAC VALVE DISEASE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3039"/>
              </event>
              <event>
                <sub_title>DEGENERATIVE MITRAL VALVE DISEASE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3039"/>
              </event>
              <event>
                <sub_title>EXTRASYSTOLES</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3039"/>
              </event>
              <event>
                <sub_title>MYOCARDIAL INFARCTION</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3039"/>
              </event>
              <event>
                <sub_title>PLEUROPERICARDITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3039"/>
              </event>
              <event>
                <sub_title>RIGHT VENTRICULAR FAILURE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3039"/>
              </event>
              <event>
                <sub_title>VENTRICULAR TACHYCARDIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3039"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>HYPERTHYROIDISM</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3039"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>EYE SWELLING</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3039"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>ABDOMINAL HERNIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3039"/>
              </event>
              <event>
                <sub_title>ABDOMINAL PAIN</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="3039"/>
              </event>
              <event>
                <sub_title>ALCOHOLIC PANCREATITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3039"/>
              </event>
              <event>
                <sub_title>ANAL FISTULA</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3039"/>
              </event>
              <event>
                <sub_title>ASCITES</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3039"/>
              </event>
              <event>
                <sub_title>CHRONIC GASTRITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3039"/>
              </event>
              <event>
                <sub_title>DIARRHOEA</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="3039"/>
              </event>
              <event>
                <sub_title>DIARRHOEA HAEMORRHAGIC</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3039"/>
              </event>
              <event>
                <sub_title>DYSPHAGIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3039"/>
              </event>
              <event>
                <sub_title>GASTROINTESTINAL DISORDER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3039"/>
              </event>
              <event>
                <sub_title>GINGIVITIS ULCERATIVE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3039"/>
              </event>
              <event>
                <sub_title>HAEMATEMESIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3039"/>
              </event>
              <event>
                <sub_title>HAEMORRHOIDS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3039"/>
              </event>
              <event>
                <sub_title>INGUINAL HERNIA</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3039"/>
              </event>
              <event>
                <sub_title>LEUKOPLAKIA ORAL</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3039"/>
              </event>
              <event>
                <sub_title>NAUSEA</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="3039"/>
              </event>
              <event>
                <sub_title>OESOPHAGITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3039"/>
              </event>
              <event>
                <sub_title>PANCREATIC CYST</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3039"/>
              </event>
              <event>
                <sub_title>PANCREATITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3039"/>
              </event>
              <event>
                <sub_title>PROCTALGIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3039"/>
              </event>
              <event>
                <sub_title>SALIVARY GLAND CYST</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3039"/>
              </event>
              <event>
                <sub_title>VOMITING</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3039"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>ASTHENIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3039"/>
              </event>
              <event>
                <sub_title>CHEST PAIN</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3039"/>
              </event>
              <event>
                <sub_title>CHILLS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3039"/>
              </event>
              <event>
                <sub_title>DRUG INTOLERANCE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3039"/>
              </event>
              <event>
                <sub_title>DRUG WITHDRAWAL SYNDROME</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3039"/>
              </event>
              <event>
                <sub_title>GENERAL PHYSICAL HEALTH DETERIORATION</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="3039"/>
              </event>
              <event>
                <sub_title>PAIN</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3039"/>
              </event>
              <event>
                <sub_title>PYREXIA</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="3039"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>HEPATIC CIRRHOSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3039"/>
              </event>
              <event>
                <sub_title>HEPATIC LESION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3039"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3039"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>AIDS DEMENTIA COMPLEX</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3039"/>
              </event>
              <event>
                <sub_title>ACQUIRED IMMUNODEFICIENCY SYNDROME</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3039"/>
              </event>
              <event>
                <sub_title>ANAL ABSCESS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3039"/>
              </event>
              <event>
                <sub_title>CHLAMYDIAL INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3039"/>
              </event>
              <event>
                <sub_title>CYTOMEGALOVIRUS COLITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3039"/>
              </event>
              <event>
                <sub_title>ENDOCARDITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3039"/>
              </event>
              <event>
                <sub_title>FUNGAL OESOPHAGITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3039"/>
              </event>
              <event>
                <sub_title>GASTROENTERITIS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3039"/>
              </event>
              <event>
                <sub_title>GASTROINTESTINAL INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3039"/>
              </event>
              <event>
                <sub_title>HELICOBACTER GASTRITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3039"/>
              </event>
              <event>
                <sub_title>HERPES VIRUS INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3039"/>
              </event>
              <event>
                <sub_title>HERPES ZOSTER</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3039"/>
              </event>
              <event>
                <sub_title>LEISHMANIASIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3039"/>
              </event>
              <event>
                <sub_title>LYMPH NODE TUBERCULOSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3039"/>
              </event>
              <event>
                <sub_title>LYMPHOGRANULOMA VENEREUM</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3039"/>
              </event>
              <event>
                <sub_title>MYCOBACTERIUM AVIUM COMPLEX INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3039"/>
              </event>
              <event>
                <sub_title>OESOPHAGEAL CANDIDIASIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3039"/>
              </event>
              <event>
                <sub_title>OPHTHALMIC HERPES ZOSTER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3039"/>
              </event>
              <event>
                <sub_title>ORAL CANDIDIASIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3039"/>
              </event>
              <event>
                <sub_title>ORAL HERPES</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3039"/>
              </event>
              <event>
                <sub_title>PNEUMOCYSTIS JIROVECII PNEUMONIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3039"/>
              </event>
              <event>
                <sub_title>PNEUMONIA</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="3039"/>
              </event>
              <event>
                <sub_title>PULMONARY TUBERCULOSIS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3039"/>
              </event>
              <event>
                <sub_title>SALMONELLOSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3039"/>
              </event>
              <event>
                <sub_title>SECONDARY TRANSMISSION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3039"/>
              </event>
              <event>
                <sub_title>SINUSITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3039"/>
              </event>
              <event>
                <sub_title>STAPHYLOCOCCAL SEPSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3039"/>
              </event>
              <event>
                <sub_title>TONSILLITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3039"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>FALL</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3039"/>
              </event>
              <event>
                <sub_title>FEMORAL NECK FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3039"/>
              </event>
              <event>
                <sub_title>LUMBAR VERTEBRAL FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3039"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>BLOOD TRIGLYCERIDES INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3039"/>
              </event>
              <event>
                <sub_title>CYTOMEGALOVIRUS TEST POSITIVE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3039"/>
              </event>
              <event>
                <sub_title>GENERAL PHYSICAL CONDITION ABNORMAL</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3039"/>
              </event>
              <event>
                <sub_title>WEIGHT DECREASED</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3039"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>DECREASED APPETITE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3039"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>ARTHRALGIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3039"/>
              </event>
              <event>
                <sub_title>INGUINAL MASS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3039"/>
              </event>
              <event>
                <sub_title>INTERVERTEBRAL DISC PROTRUSION</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3039"/>
              </event>
              <event>
                <sub_title>OSTEONECROSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3039"/>
              </event>
              <event>
                <sub_title>OSTEOPOROSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3039"/>
              </event>
              <event>
                <sub_title>PAIN IN EXTREMITY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3039"/>
              </event>
              <event>
                <sub_title>SPINAL PAIN</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3039"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>ANAL CANCER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3039"/>
              </event>
              <event>
                <sub_title>ANAPLASTIC LARGE CELL LYMPHOMA T- AND NULL-CELL TYPE STAGE IV</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3039"/>
              </event>
              <event>
                <sub_title>ANOGENITAL WARTS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3039"/>
              </event>
              <event>
                <sub_title>BURKITT'S LYMPHOMA</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3039"/>
              </event>
              <event>
                <sub_title>EXTRANODAL MARGINAL ZONE B-CELL LYMPHOMA (MALT TYPE)</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3039"/>
              </event>
              <event>
                <sub_title>HEPATIC CANCER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3039"/>
              </event>
              <event>
                <sub_title>KAPOSI'S SARCOMA</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3039"/>
              </event>
              <event>
                <sub_title>PAPILLOMA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3039"/>
              </event>
              <event>
                <sub_title>PLASMABLASTIC LYMPHOMA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3039"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>ATAXIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3039"/>
              </event>
              <event>
                <sub_title>BALANCE DISORDER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3039"/>
              </event>
              <event>
                <sub_title>CEREBRAL ARTERIOSCLEROSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3039"/>
              </event>
              <event>
                <sub_title>CEREBRAL ATROPHY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3039"/>
              </event>
              <event>
                <sub_title>CEREBRAL INFARCTION</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3039"/>
              </event>
              <event>
                <sub_title>DISTURBANCE IN ATTENTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3039"/>
              </event>
              <event>
                <sub_title>FACIAL PARESIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3039"/>
              </event>
              <event>
                <sub_title>HEADACHE</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3039"/>
              </event>
              <event>
                <sub_title>HYPOAESTHESIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3039"/>
              </event>
              <event>
                <sub_title>MEMORY IMPAIRMENT</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3039"/>
              </event>
              <event>
                <sub_title>MENINGEAL DISORDER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3039"/>
              </event>
              <event>
                <sub_title>PARAESTHESIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3039"/>
              </event>
              <event>
                <sub_title>RADICULOPATHY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3039"/>
              </event>
              <event>
                <sub_title>SOMNOLENCE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3039"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>ABORTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3039"/>
              </event>
              <event>
                <sub_title>ABORTION MISSED</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3039"/>
              </event>
              <event>
                <sub_title>ABORTION SPONTANEOUS</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3039"/>
              </event>
              <event>
                <sub_title>MATERNAL CONDITION AFFECTING FOETUS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3039"/>
              </event>
              <event>
                <sub_title>PLACENTAL INSUFFICIENCY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3039"/>
              </event>
              <event>
                <sub_title>PREMATURE BABY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3039"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>APATHY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3039"/>
              </event>
              <event>
                <sub_title>CONFUSIONAL STATE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3039"/>
              </event>
              <event>
                <sub_title>DELIRIUM</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3039"/>
              </event>
              <event>
                <sub_title>DEPRESSION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3039"/>
              </event>
              <event>
                <sub_title>DISORIENTATION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3039"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>HYDRONEPHROSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3039"/>
              </event>
              <event>
                <sub_title>NEPHROLITHIASIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3039"/>
              </event>
              <event>
                <sub_title>NOCTURIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3039"/>
              </event>
              <event>
                <sub_title>RENAL CYST</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3039"/>
              </event>
              <event>
                <sub_title>RENAL FAILURE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3039"/>
              </event>
              <event>
                <sub_title>URINARY BLADDER POLYP</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3039"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>ADENOMYOSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3039"/>
              </event>
              <event>
                <sub_title>MENOMETRORRHAGIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3039"/>
              </event>
              <event>
                <sub_title>PROSTATIC MASS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3039"/>
              </event>
              <event>
                <sub_title>VAGINAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3039"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>CHRONIC OBSTRUCTIVE PULMONARY DISEASE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3039"/>
              </event>
              <event>
                <sub_title>COUGH</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3039"/>
              </event>
              <event>
                <sub_title>DYSPNOEA</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3039"/>
              </event>
              <event>
                <sub_title>LUNG INFILTRATION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3039"/>
              </event>
              <event>
                <sub_title>OROPHARYNGEAL PAIN</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3039"/>
              </event>
              <event>
                <sub_title>RALES</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3039"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>ABORTION INDUCED</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3039"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Global Medical Services</name_or_title>
      <organization>AbbVie (prior sponsor Abbott)</organization>
      <phone>800-633-9110</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

